Original Study| Volume 15, ISSUE 6, e1069-e1072, December 2017

Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry

Published:August 08, 2017DOI:



      The 5-year overall survival (OS) of patients with metastatic renal cell carcinoma (mRCC) has been rarely reported. The aim of the RENSUR5 registry study was to obtain real-world data on the use of therapy for mRCC and assess the 5-year OS in the Russian population.

      Patient and Methods

      Patients were retrospectively identified at 11 cancer centers in different regions of Russia (Astrakhan, Barnaul, Ekaterinburg, Kazan, Krasnoyarsk, Obninsk, Omsk, Rostov-on-Don, Samara, St. Petersburg, and Ufa). Patients were included if mRCC had been diagnosed from January 2010 to January 2011. Anonymized data were collected through an online registry covering the demographic data, treatments, and outcomes.


      A total of 439 adult mRCC patients were included in the present study for analysis. The mean age at diagnosis of mRCC was 60.9 years (range, 33-90 years; with 9% of patients aged ≥ 75 years). The patients were predominantly men (70.2%) and 67.7% had nephrectomy. Clear cell and non–clear cell tumors were detected in 61.1% and 7.7% of patients, respectively. A total of 271 patients (62%) received systemic therapy. The median duration of therapy was 11 months (95% confidence interval, 9.5-12.5 months). Most treatment was with interferon only (n = 145); 105 patients (23.9%) received targeted therapy, and 69 patients (15.7%) received ≥ 2 treatment lines. The 1-, 3-, and 5-year OS rate was 49.4%, 18.9%, and 8.2%, respectively. The median OS from the start of treatment was 12 months (95% confidence interval, 9.7-14.4 months).


      RENSUR5 is a large real-world database assessing the mRCC treatment patterns and 5-year OS in Russia. According to the first results of the present study, we believe that 5-year OS should improve with novel therapies. The limited administration of targeted therapies was reflected by the results of the 5-year survival rate. The treatment of mRCC has changed in the past years with new treatment options significantly improving OS. The 5-year OS of patients treated with immunotherapy and targeted therapy should be analyzed in the real world.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kaprin A.
        • Starinskiy V.
        • Petrova G.
        Malignant Tumors in Russia in 2015 (Morbidity and Mortality).
        Russian Ministry of Health, Moscow2017
        • Tsimafeyeu I.
        • Aksel E.
        Renal cell carcinoma in the Russian Federation in 2008.
        Malign Tumours. 2010; 1: 1-4
        • National Comprehensive Cancer Network
        NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, version 2.2017.
        (Available at:) (Accessed: August 31, 2017)
        • Tsimafeyeu I.
        • Zart J.S.
        • Chung B.
        Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
        BJU Int. 2013; 112: 32-38
        • Nosov D.
        • Vorobyov N.
        • Gladkov O.
        • et al.
        RUSSCO clinical practice guidelines: kidney cancer.
        Malign Tumours. 2015; 4: 281-288
        • National Cancer Institute
        SEER Cancer Stat Facts: Kidney and Renal Pelvis Cancer.
        (Available at:) (Accessed: August 31, 2017)
      1. Cancer Research UK.
        (Available at:) (Accessed: August 31, 2017)
      2. National Cancer Registration Service, Eastern Office.
        (Available at:) (Accessed: August 31, 2017)
        • Wahlgren T.
        • Harmenberg U.
        • Sandström P.
        • et al.
        Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008).
        Br J Cancer. 2013; 108: 1541-1549
        • Rini B.I.
        • de La Motte Rouge T.
        • Harzstark A.L.
        • et al.
        Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib.
        Clin Genitourin Cancer. 2013; 11: 107-114
        • McDermott D.F.
        • Motzer R.J.
        • Atkins M.B.
        • et al.
        Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.
        J Clin Oncol. 2016; 34 (abstract 4507)
        • Tsimafeyeu I.
        • Zolotareva T.
        • Varlamov S.
        • et al.
        Five-year overall survival among patients with metastatic renal cell carcinoma: results of Russian population-based study RENSUR5.
        J Clin Oncol. 2017; 35 (abstract 20)